Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective.

Balf G, Stewart TD, Whitehead R, Baker RA.

Prim Care Companion J Clin Psychiatry. 2008;10(1):15-24.

2.
3.

Metabolic monitoring for patients treated with antipsychotic medications.

Cohn TA, Sernyak MJ.

Can J Psychiatry. 2006 Jul;51(8):492-501. Review.

PMID:
16933586
4.

[Schizophrenia, diabetes mellitus and antipsychotics].

Gury C.

Encephale. 2004 Jul-Aug;30(4):382-91. Review. French.

PMID:
15538314
5.
6.

Atypical antipsychotics and glucose homeostasis.

Bergman RN, Ader M.

J Clin Psychiatry. 2005 Apr;66(4):504-14. Review.

PMID:
15816794
7.

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders.

Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders.

Aust N Z J Psychiatry. 2005 Jan-Feb;39(1-2):1-30. Review.

PMID:
15660702
8.

Metabolic syndrome and mental illness.

Newcomer JW.

Am J Manag Care. 2007 Nov;13(7 Suppl):S170-7. Review. Erratum in: Am J Manag Care. 2008 Feb;14(2):76.

9.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
10.

Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

Citrome L, Holt RI, Walker DJ, Hoffmann VP.

Clin Drug Investig. 2011;31(7):455-82. doi: 10.2165/11589060-000000000-00000. Review.

PMID:
21495734
11.

Treatment of co-morbid mental illness in primary care: how to minimize weight gain, diabetes, and metabolic syndrome.

Gibson M, Carek PJ, Sullivan B.

Int J Psychiatry Med. 2011;41(2):127-42. Review.

PMID:
21675345
12.

Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians.

Hasnain M, Vieweg WV, Hollett B.

Postgrad Med. 2012 Jul;124(4):154-67. doi: 10.3810/pgm.2012.07.2577. Review.

PMID:
22913904
13.

Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity.

Van Gaal LF.

Eur Neuropsychopharmacol. 2006 Sep;16 Suppl 3:S142-8. Epub 2006 Jul 24. Review.

PMID:
16863690
14.

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.

McIntyre RS, McCann SM, Kennedy SH.

Can J Psychiatry. 2001 Apr;46(3):273-81. Review.

PMID:
11320682
15.

Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring.

De Hert M, van Eyck D, De Nayer A.

Int Clin Psychopharmacol. 2006 Mar;21 Suppl 2:S11-5. Review.

PMID:
16601508
16.
17.
18.

[Diabetes and second-generation (atypical) antipsychotics].

Chabroux S, Haffen E, Penfornis A.

Ann Endocrinol (Paris). 2009 Sep;70(4):202-10. doi: 10.1016/j.ando.2009.07.003. Epub 2009 Aug 22. Review. French.

PMID:
19700142
19.

Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins.

Andrade C.

Bipolar Disord. 2013 Dec;15(8):813-23. doi: 10.1111/bdi.12130. Epub 2013 Oct 10. Review.

PMID:
24119211
20.

Antipsychotic medications: metabolic and cardiovascular risk.

Newcomer JW.

J Clin Psychiatry. 2007;68 Suppl 4:8-13. Review.

Items per page

Supplemental Content

Write to the Help Desk